Overview

Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The objective of this study was to characterize the effects of two dose combinations of tipranavir/ritonavir (TPV 500 mg/RTV 100 mg and TPV 750 mg/RTV 200 mg), administered daily and BID, on the pharmacokinetics of efavirenz (EFV), 600 mg daily

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Efavirenz
Ritonavir
Tipranavir